Champions Oncology (CSBR) Cost of Revenue (2010 - 2026)

Champions Oncology's Cost of Revenue history runs 17 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 59.71% year-over-year to $2.7 million; the TTM figure through Jan 2026 stood at $19.1 million (up 215.99% YoY), while the FY2025 annual figure was $28.4 million, up 301.88% from the prior year.
• Cost of Revenue was $2.7 million for Q1 2026 at Champions Oncology, down from $7.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $18.9 million in Q2 2022 to a low of -$15.1 million in Q2 2024.
• Historically, Cost of Revenue has averaged $5.0 million across 5 years, with a median of $7.1 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue soared 1181.79% in 2022, then plunged 305.6% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $7.4 million in 2022, then fell by 11.08% to $6.6 million in 2023, then increased by 12.24% to $7.4 million in 2024, then fell by 2.23% to $7.3 million in 2025, then sank by 63.29% to $2.7 million in 2026.
• The last three Cost of Revenue figures came in at $2.7 million (Q1 2026), $7.3 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.